Benzothiazole-based apoptosis inducers: A comprehensive overview and future prospective

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Cancer incidence and prevalence are increasing globally, necessitating novel therapeutic agents.
• Existing anticancer drugs face challenges like drug resistance and adverse effects.
• Heterocyclic compounds, particularly benzothiazole derivatives, show promise for developing new anticancer drugs.

Purpose of the Study:

• To provide a comprehensive overview of benzothiazole derivatives as potential anticancer agents.
• To evaluate their antiproliferative activity, mechanism of action, and enzyme inhibition.
• To explore the structure-activity relationship of these compounds.

Main Methods:

• Synthesis and characterization of benzothiazole derivatives.
• In vitro assessment of antiproliferative activity.
• Apoptosis induction assays (intrinsic pathway).
• Enzyme inhibition studies (Aurora kinase, EGFR, VEGFR, PI3K, topoisomerase, tubulin).

Main Results:

• Benzothiazole derivatives demonstrated significant dose-dependent antiproliferative activity.
• Compounds induced apoptosis through the intrinsic pathway.
• Inhibition of key cancer-related enzymes including Aurora kinase, EGFR, VEGFR, PI3K, topoisomerase, and tubulin was observed.
• Structure-activity relationship analysis provided insights into effective molecular design.

Conclusions:

• Benzothiazole derivatives represent a promising scaffold for developing novel anticancer drugs.
• These compounds exhibit potent anticancer effects via apoptosis induction and enzyme inhibition.
• Further research into benzothiazole-based therapeutics could lead to improved cancer treatment strategies.